
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
SGS Leverages Phase Forward's InForm and Central Designer Solutions for Greater Clinical Trial Efficiencies






